Heyman Richard A. 4
4 · Oric Pharmaceuticals, Inc. · Filed Jul 8, 2026
Research Summary
AI-generated summary of this filing
Oric Pharmaceuticals (ORIC) Director Richard Heyman Sells 300 Shares
What Happened Richard A. Heyman, a director of Oric Pharmaceuticals, reported the sale of 300 shares on July 6, 2026. The shares were disposed at $12.00 each for a total value of $3,600. The filing shows the sale was made pursuant to a pre-established Rule 10b5-1 trading plan.
Key Details
- Transaction date and price: 2026-07-06, 300 shares sold at $12.00 per share.
- Total proceeds: $3,600.
- Shares held/ownership: Shares are held of record by RAHD Capital, LLC; Heyman has voting and investment power over those shares (no post-transaction total reported on this Form 4).
- Footnotes: F1 — sale effected under a Rule 10b5-1 plan; F2 — shares held by RAHD Capital, LLC with Heyman having voting/investment power.
- Filing timing: Form was filed 2026-07-08 for a 2026-07-06 transaction — appears to be filed within the usual two-business-day window.
Context This was a sale (disposition), not a purchase or option exercise. Sales under 10b5-1 plans are typically prearranged and considered routine; they do not necessarily indicate a change in the director’s view of the company.
Insider Transaction Report
Form 4
Heyman Richard A.
Director
Transactions
- Sale
Common Stock
[F1][F2]2026-07-06$12.00/sh−300$3,600→ 212,772 total(indirect: See footnote)
Holdings
- 41,800
Common Stock
Footnotes (2)
- [F1]The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
- [F2]The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
Signature
/s/ Christian Kuhlen, attorney-in-fact|2026-07-08